Atossa Therapeutics - Owah-owahan pendapatan YoY sajrone 12 wulan kepungkur ATOS

Logo grafis Atossa Pharma (ATOS)

Atossa Therapeutics develops targeted breast cancer therapies, leveraging patent protection amidst costly R&D expenditures. The monetization of unique formulas ensures long-term demand for its drugs. The current year-over-year revenue growth rate (TTM) is recorded at 0.00, confirming the company's financial momentum. Looking ahead, Atossa Therapeutics plans to complete clinical phases and secure a major licensing partner.

Wutah dodolan YoY sajrone rolas wulan kepungkur Atossa (ATOS): kanggo periode 11.02.2024 - 15.11.2026

atossatherapeutics.com (ATOS) - rincian metrik lan laporan keuangan

- rega pasar lan target rega analis:
Pambiji fundamental perusahaan:Atossa Therapeutics
Produk mawa merek Atossa Therapeutics

For Atossa Therapeutics (ATOS), whose success depends on Endoxifen clinical trials within the defensive oncology sector, the TTM annual revenue growth serves as an indicator of development commercialization. This metric compares revenue over the last twelve months with the same period last year, allowing investors to filter out market noise and avoid freezing capital in the event of negative fundamental sales trends.